Startups

With an AI-driven platform, BioCurie attempts to transform cell and gene therapy manufacturing

When the Wilmington biopharma company won the first Cure Xchange Challenge, its founder was the only woman CEO on stage.

Cure CEO Seema Kumar, BioCurie CEO Irene Rombel and Chelsea Clinton at the Cure Xchange Challenge event. (Courtesy BioCurie)
When Wilmington-based biotech company BioCurie became one of seven AI-based healthcare startups to win the inaugural Cure Xchange Challenge in New York City, Dr. Irene Rombel couldn’t help noticing something.

Rombel, who cofounded BioCurie with MIT professor Richard Braatz in 2021, was the only woman CEO representing a winning startup on the stage.

In the world of biotech startups, it wasn’t a surprise. 

“I was the only one!” Rombel told Technical.ly. “But it’s not unusual.” 

Based on her company’s name, it’s probably not surprising that Rombel looked up to the physicist and chemist Marie Curie during her childhood. Growing up in a working-class home with Polish immigrant parents, Rombel saw the Polish-born Curie as a role model. Rombel studied biochemistry, eventually earning a Ph.D. at the University of Otago in New Zealand. She’s been an assistant professor, an investor, a consultant and a senior director of strategic analysis at Johnson & Johnson.

“[At Johnson & Johnson] I saw these life-saving therapies that are really going to transform human life, cure diseases that currently have no treatments,” Rombel said. “But then I realized, these are really, really hard to develop and to produce and, sure enough, they cost a lot of money for the patient, which is not tenable.” 

It was the same at Philadelphia-based Spark Therapeutics, where she went on to work as chief of staff for research.

Around that time, Rombel first met Braatz at a NIIMBL (The National Institute for Innovation in Manufacturing Biopharmaceuticals) conference where he was speaking.

“I’d read his research because he developed some of the first AI models for gene therapy production and is a world leader in artificial intelligence for biomanufacturing,” Rombel said. “And he had the same vision that I had.”

Braatz and Rombel decided to join forces and cofound BioCurie to revolutionize cell and gene therapy manufacturing.

“We don’t want to do something that’s just going to be incremental,” Rombel said. “We want to have something that’s really going to impact the industry and our most important patients.”

BioCurie’s proprietary AI-driven technology is called the mAI-BioCurie platform. Instead of empirical experiments in a lab, the software produces a digital twin on which it runs millions of experiments to find solutions faster and ensure consistency in manufacturing. Ultimately, it should reduce the cost of developing therapies, making them more affordable for patients.

“Essentially, we’re developing the first AI-driven software platform to help biopharmaceutical companies and manufacturers figure out the optimal recipe,” Rombel said. “It sounds simple, but it’s so hard.”

As winners of the Cure Exchange Challenge, BioCurie has access to seed funding and is now part of a one-year residency at Cure’s New York City campus incubator.

“We hope to have raised our pre-seed and possibly even our seed round in a year,” Rombel said. 

If all goes to plan, BioCurie will forge strategic partnerships and launch its first product by the end of the residency. 

Rombel plans to stay in Delaware, where, among other things, she mentors students at Delaware Technical and Community College. The commute to Cure’s campus is less than two hours by train.

“The company is physically based in Wilmington, and Richard is up [in Boston] at MIT,” Rombel said. “So now we’ll have a presence in New York, Greater Philly and right in the heart of Philadelphia.”

With the US Economic Development Administration’s selection of The Greater Philadelphia Region Precision Medicine Tech Hub last fall, BioCurie, which very much fits the definition of precision medicine, is right where it needs to be, Rombel said. 

“This is such a great region,” she said. “The first gene therapy came out of CHOP [Children’s Hospital of Philadelphia], the first cell therapy came out of UPenn, the first mRNA vaccine came out of Penn. And then there are all these spinouts, and now there’s us.”

Irene Rombel will give a virtual talk, “Pioneering BioCurie’s Vision,” on LinkedIn Live on March 12 and 12:30 pm, as part of Cure’s Tuesday Talks series.

Before you go...

Please consider supporting Technical.ly to keep our independent journalism strong. Unlike most business-focused media outlets, we don’t have a paywall. Instead, we count on your personal and organizational support.

3 ways to support our work:
  • Contribute to the Journalism Fund. Charitable giving ensures our information remains free and accessible for residents to discover workforce programs and entrepreneurship pathways. This includes philanthropic grants and individual tax-deductible donations from readers like you.
  • Use our Preferred Partners. Our directory of vetted providers offers high-quality recommendations for services our readers need, and each referral supports our journalism.
  • Use our services. If you need entrepreneurs and tech leaders to buy your services, are seeking technologists to hire or want more professionals to know about your ecosystem, Technical.ly has the biggest and most engaged audience in the mid-Atlantic. We help companies tell their stories and answer big questions to meet and serve our community.
The journalism fund Preferred partners Our services
Engagement

Join our growing Slack community

Join 5,000 tech professionals and entrepreneurs in our community Slack today!

Trending

19 tech and entrepreneurship events to check out before the holidays

EDA officials are ‘hopeful’ Tech Hubs program will live on under Trump

AI is being used in more and more of the hiring process, especially at high-volume companies

Delaware students take a field trip to China using their tablets and ChatGPT

Technically Media